Abbisko Therapeutics

Three blocks displaying from left to right a person a handshake and another person
Biotech

Merck KGaA pays $85M for global rights to Abbisko's tumor drug

With the CSF-1R inhibitor space heating up, Germany's Merck has gone all-in on pimicotinib, paying Abbisko $85 million for the global license.
James Waldron Apr 1, 2025 7:40am
Graphic image of a fishing line looking to hook onto 100 bills underwater

Merck KGaA tacks on Abbisko’s joint tumor med for $70M upfront

Dec 4, 2023 10:26am
Lilly

Lilly extends JPM collab theme in $1B Evotec pact, Abbisko deal

Jan 18, 2022 11:30am
Chinese scientist

Chinese I-O biotech Abbisko raises $28M in first-round funding

Feb 8, 2017 8:53am